Figure 7
From: PPARα activation protects against cholestatic liver injury
Therapeutic effect of fenofibrate against ANIT-induced cholestasis in control, ANIT, 24 h, 12 h and 2 h groups. (a) Phenotype and H&E staining of liver. (b) Serum AST, ALT, and ALP enzyme activity. (c) QPCR analysis of inflammatory factors in liver. Values represented fold change after normalization to control. (d) Long-chain acylcarnitine levels. (e) Bile acids levels. All data were repressed as mean ± SEM (n = 5). *P < 0.05, **P < 0.01, and ***P < 0.001 verse control; # P < 0.05, ## P < 0.01, and ### P < 0.001 verse ANIT.
